X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Medicare Monday: How finding an Alzheimer’s treatment could lower Medicare spending

By Nicole Longo  |    May 8, 2017
Alzheimer’s disease is devastating and impacts more than 5.5 million Americans and their families. While America’s biopharmaceutical researchers have been working tirelessly to find a cure for the...   Read More

Fighting disease Together: New ads feature patients and the researchers behind today’s breakthroughs

By Robert Zirkelbach  |    April 19, 2017
Today, we launched our next wave of advertising as part of the GOBOLDLY™ campaign, titled Together, featuring the stories of researchers developing cutting-edge breakthroughs alongside patients...   Read More

Continuing the search for new Alzheimer’s therapies

By Nicole Longo  |    November 10, 2016
Designated in 1983 by then-President Ronald Reagan, November marks National Alzheimer’s Disease Awareness Month – a month for all Americans to come together to raise awareness and understanding of...   Read More

Dr. George Scangos: Not just science for science’s sake

By Andrew Powaleny  |    August 10, 2016
America’s biopharmaceutical researchers are working tirelessly to develop new and innovative medicines for patients. For those diseases that have no treatment options, the opportunity to improve...   Read More

Using setbacks as stepping stones in Alzheimer’s research

By Gretta Stone  |    August 3, 2016
For decades, biopharmaceutical researchers have worked tirelessly in the pursuit of new treatments and cures for the costly and devastating Alzheimer’s disease. Advancing treatments for...   Read More

Biopharmaceutical industry is essential to development of Alzheimer’s treatments

By Holly Campbell  |    December 23, 2015
This week, presidential candidate Hillary Clinton called for a spending increase by the federal government to find a cure to the costly and devastating Alzheimer’s disease. Finding a better...   Read More

Week in Review: The Latest from PhRMA

By Priscilla VanderVeer  |    July 17, 2015
Neurological Disorders: America’s biopharmaceutical companies are committed to developing innovative new treatments for the nearly 50 million Americans affected by neurological disorders. This...   Read More

In Case You Missed It: Progress and Promise in Alzheimer’s Research

By Tina Stow  |    July 15, 2015
PhRMA recently convened a panel of health care experts for a live webcast discussion about the current state of research to treat and care for Alzheimer’s disease. Dr. Bill Chin of PhRMA moderated...   Read More

The War on Alzheimer’s: Progress and Challenges of Biopharmaceutical Research

By Bill Chin, M.D.  |    July 15, 2015
Alzheimer’s disease steals memories, relationships and independence. It is a ruthless, devastating disease ravaging more than 5 million people in the United States alone, and is the sixth-leading...   Read More

New PhRMA and Epilepsy Foundation Report: 420 Medicines in Development for Neurological Disorders

By Tina Stow  |    July 13, 2015
It’s hard to imagine, but there are currently more than 50 million Americans – nearly one-sixth of our population – affected by some type of neurological disorder. While some of these are more...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates